# GeDiPNet Cluster 10 -- Top Shared Genes -- generated 2026-10-09 14:24:58
# Curated genes (disease_gdp) linked to 2 or more of this cluster's member diseases, most widely shared first. Data as of: 2026-10-09 03:15:01.
Gene	Member Diseases Linked	Cluster Size	Linked Diseases
DRD2	14	29	Amphetamine or sympathomimetic abuse; Bradycardia; Catalepsy; Chiari-frommel syndrome; Delirium; Disruptive impulse-control and conduct disorder; Dyskinesia, drug-induced; Hyperkinesia; Hyperproinsulinemia; Hypotension; Movement disorder; Myoclonic dystonia; Pituitary neoplasms; Seizures
DRD3	9	29	Amphetamine or sympathomimetic abuse; Delirium; Disruptive impulse-control and conduct disorder; Dyskinesia, drug-induced; Essential tremor; Hyperalgesia; Hyperkinesia; Movement disorder; Seizures
PDYN	8	29	Amnesia; Amphetamine or sympathomimetic abuse; Bradycardia; Dyskinesia, drug-induced; Hyperalgesia; Hypotension; Movement disorder; Seizures
DRD1	7	29	Amphetamine or sympathomimetic abuse; Catalepsy; Dyskinesia, drug-induced; Hyperkinesia; Hypotension; Movement disorder; Seizures
PRL	7	29	Bradycardia; Catalepsy; Chiari-frommel syndrome; Disruptive impulse-control and conduct disorder; Hyperproinsulinemia; Hypotension; Pituitary neoplasms
ADORA2A	6	29	Amphetamine or sympathomimetic abuse; Hyperkinesia; Hypotension; Movement disorder; Seizures; Substance-induced psychosis
IL6	6	29	Amnesia; Delirium; Edema; Hyperalgesia; Hypotension; Seizures
POMC	6	29	Amnesia; Bradycardia; Catalepsy; Edema; Hypotension; Seizures
AGT	5	29	Bradycardia; Catalepsy; Hyperalgesia; Hypotension; Seizures
CNR1	5	29	Catalepsy; Hyperalgesia; Hypotension; Movement disorder; Seizures
GAD1	5	29	Amphetamine or sympathomimetic abuse; Chiari-frommel syndrome; Dyskinesia, drug-induced; Hyperproinsulinemia; obsolete early infantile epileptic encephalopathy
IGF1	5	29	Delirium; Essential tremor; Hyperalgesia; Movement disorder; Pituitary neoplasms
OPRM1	5	29	Amphetamine or sympathomimetic abuse; Hyperalgesia; Movement disorder; Seizures; Substance-induced psychosis
TAC1	5	29	Amnesia; Bradycardia; Edema; Hyperalgesia; Hypotension
CALCA	4	29	Catalepsy; Edema; Hyperalgesia; Hyperkinesia
CAT	4	29	Dyskinesia, drug-induced; Edema; Hypotension; Seizures
CCK	4	29	Catalepsy; Dyskinesia, drug-induced; Hyperkinesia; Seizures
CRH	4	29	Bradycardia; Hypotension; Movement disorder; Seizures
FOS	4	29	Amphetamine or sympathomimetic abuse; Hyperalgesia; Hyperkinesia; Seizures
GCG	4	29	Bradycardia; Catalepsy; Hyperkinesia; Hypotension
GSTP1	4	29	Amphetamine or sympathomimetic abuse; Essential tremor; Movement disorder; Substance-induced psychosis
INS	4	29	Edema; Hyperproinsulinemia; Hypotension; Seizures
KNG1	4	29	Bradycardia; Edema; Hyperalgesia; Hypotension
NGF	4	29	Amnesia; Hyperalgesia; Hyperkinesia; Seizures
OXT	4	29	Edema; Hyperkinesia; Hypotension; Seizures
SLC6A3	4	29	Amphetamine or sympathomimetic abuse; Delirium; Hyperkinesia; Substance-induced psychosis
TH	4	29	Catalepsy; Delirium; Dyskinesia, drug-induced; Hyperkinesia
TRH	4	29	Amnesia; Bradycardia; Catalepsy; Seizures
ACHE	3	29	Amphetamine or sympathomimetic abuse; Movement disorder; Seizures
ADORA1	3	29	Bradycardia; Catalepsy; Hypotension
APOE	3	29	Amnesia; Delirium; Seizures
AVP	3	29	Amnesia; Hyperalgesia; Hypotension
CNTNAP5	3	29	Essential tremor; Movement disorder; Periodic limb movement disorder
CXCL8	3	29	Delirium; Edema; Hyperalgesia
EDN1	3	29	Bradycardia; Hyperalgesia; Hypotension
FOSB	3	29	Disruptive impulse-control and conduct disorder; Dyskinesia, drug-induced; Movement disorder
GDNF	3	29	Amphetamine or sympathomimetic abuse; Dyskinesia, drug-induced; Hyperalgesia
GNRH1	3	29	Bradycardia; Chiari-frommel syndrome; Hyperproinsulinemia
HCN1	3	29	Movement disorder; Periodic limb movement disorder; Seizures
HTR1A	3	29	Bradycardia; Seizures; Substance-induced psychosis
HTR1B	3	29	Amphetamine or sympathomimetic abuse; Hypotension; Seizures
IL1A	3	29	Amnesia; Hyperalgesia; Hypotension
IL1B	3	29	Hyperalgesia; Hypotension; Seizures
IL2	3	29	Amnesia; Hyperkinesia; Hypotension
LHB	3	29	Bradycardia; Chiari-frommel syndrome; Hyperproinsulinemia
MAP2K5	3	29	Amphetamine or sympathomimetic abuse; Movement disorder; Periodic limb movement disorder
NOS1	3	29	Amphetamine or sympathomimetic abuse; Hyperalgesia; Seizures
NTS	3	29	Bradycardia; Catalepsy; Hyperkinesia
PRLR	3	29	Chiari-frommel syndrome; Hyperproinsulinemia; Hyperprolactinemia
PTGS2	3	29	Edema; Hyperalgesia; Seizures
RGS9	3	29	Bradyopsia; Dyskinesia, drug-induced; Substance-induced psychosis
SLC12A5	3	29	Hyperalgesia; Movement disorder; Seizures
TNF	3	29	Edema; Hyperalgesia; Hypotension
VIP	3	29	Edema; Hyperalgesia; Hypotension
ACE	2	29	Hypotension; Substance-induced psychosis
ADRA1B	2	29	Hypotension; Seizures
AKT1	2	29	Amphetamine or sympathomimetic abuse; Substance-induced psychosis
BCHE	2	29	Hyperkinesia; Seizures
BDKRB2	2	29	Hyperalgesia; Hypotension
BDNF	2	29	Amphetamine or sympathomimetic abuse; Seizures
BTBD9	2	29	Movement disorder; Periodic limb movement disorder
CACNA1D	2	29	Bradycardia; Edema
CASD1	2	29	Movement disorder; Myoclonic dystonia
CCDC148	2	29	Movement disorder; Periodic limb movement disorder
CDKN1B	2	29	multiple endocrine neoplasia type 4; Pituitary neoplasms
CHRM2	2	29	Bradycardia; Neurogenic bladder
CNR2	2	29	Catalepsy; Hyperalgesia
COMT	2	29	Amphetamine or sympathomimetic abuse; Hyperalgesia
CRHR1	2	29	Hyperalgesia; Hyperkinesia
CTNNA3	2	29	Edema; Essential tremor
CYP2D6	2	29	Amphetamine or sympathomimetic abuse; Bradycardia
DPP6	2	29	Essential tremor; Movement disorder
EDN2	2	29	Bradycardia; Hypotension
EDN3	2	29	Bradycardia; Hypotension
EMB	2	29	Movement disorder; Periodic limb movement disorder
GABBR1	2	29	Amphetamine or sympathomimetic abuse; Hyperkinesia
GABRA1	2	29	Essential tremor; Seizures
GABRG2	2	29	Amphetamine or sympathomimetic abuse; Seizures
GAD2	2	29	Amphetamine or sympathomimetic abuse; Seizures
GEMIN5	2	29	Essential tremor; neurodevelopmental disorder with cerebellar atrophy and motor dysfunction
GNAI1	2	29	Amnesia; Essential tremor
GNAO1	2	29	Essential tremor; Movement disorder
GRIA1	2	29	Hyperkinesia; Hypotension
GRIA2	2	29	Hyperkinesia; neurodevelopmental disorder with language impairment and behavioral abnormalities
GRIN2B	2	29	Hyperalgesia; Hypotension
GRM2	2	29	Amphetamine or sympathomimetic abuse; Substance-induced psychosis
GSTM1	2	29	Amphetamine or sympathomimetic abuse; Movement disorder
HTR2A	2	29	Hyperalgesia; Hyperkinesia
HTR6	2	29	Amphetamine or sympathomimetic abuse; Substance-induced psychosis
IL1RN	2	29	Delirium; Hyperalgesia
LMO1	2	29	Movement disorder; Periodic limb movement disorder
MECP2	2	29	Hyperalgesia; Seizures
MEIS1	2	29	Movement disorder; Periodic limb movement disorder
MYT1	2	29	Movement disorder; Periodic limb movement disorder
NISCH	2	29	Bradycardia; Hypotension
NKAIN2	2	29	Essential tremor; Hypotension
NLRP1	2	29	Essential tremor; Hypotension
NOS2	2	29	Hyperalgesia; Seizures
NPY	2	29	Hyperkinesia; Seizures
NPY1R	2	29	Amphetamine or sympathomimetic abuse; Substance-induced psychosis
NRG1	2	29	Amphetamine or sympathomimetic abuse; Movement disorder
NRROS	2	29	Seizures; seizures, early-onset, with neurodegeneration and brain calcifications
PGR	2	29	Chiari-frommel syndrome; Hyperproinsulinemia
PICK1	2	29	Amphetamine or sympathomimetic abuse; Substance-induced psychosis
PLAT	2	29	Amphetamine or sympathomimetic abuse; Hypotension
PNOC	2	29	Hyperalgesia; Hypotension
PREP	2	29	Amnesia; Retrograde amnesia
PSD3	2	29	Amphetamine or sympathomimetic abuse; Essential tremor
PTHLH	2	29	Edema; Hyperalgesia
PTPRD	2	29	Movement disorder; Periodic limb movement disorder
SCN1A	2	29	Movement disorder; Seizures
SCN2A	2	29	Movement disorder; Seizures
SGCE	2	29	Movement disorder; Myoclonic dystonia
SIGMAR1	2	29	Amnesia; Seizures
SLC9A3	2	29	Edema; Hypotension
SNCA	2	29	Amphetamine or sympathomimetic abuse; Substance-induced psychosis
SOD2	2	29	Seizures; Substance-induced psychosis
STK33	2	29	Movement disorder; Periodic limb movement disorder
SYN2	2	29	Hyperalgesia; Seizures
TACR1	2	29	Bradycardia; Hyperalgesia
UTS2	2	29	Bradycardia; Movement disorder
WSCD1	2	29	Essential tremor; Hypotension